Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Frank C. Passero, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



As a physician I aim to provide patients with an understanding of their medical condition and guidance as they navigate complex medical decisions. I consider honesty, compassion and my medical knowledge as foundational principles upon which I seek to build a trusting patient-physician relationship. Getting to know my patients, their unique circumstances and goals is a key aspect of my practice, in order to provide patients with a personalized plan of care.

I obtained my medical degree from Jefferson Medical College in Philadelphia, Pennsylvania and went on to complete internship, residency, and a chief medical residency in Internal Medicine at Scripps Mercy Hospital in San Diego. I pursued my Hematology and Oncology fellowship training at Tufts Medical Center in Boston, Massachusetts where I carried out laboratory research studying the effects of proteasome and HDAC inhibitors in lymphoma.

I have a special interest in plasma cell disorders including myeloma and amyloidosis, and would like to provide patients with the opportunity to participate in well-designed clinical trials for these and other related diseases.



  • Hematology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine


MD | Thomas Jefferson University

Post-doctoral Training & Residency

07/01/2014 - 06/30/2017
Fellowship in Hematology/Oncology at Tufts Medical Center

07/01/2011 - 06/30/2014
Residency in Internal Medicine at Mercy Hospital and Medical Center

6/24//2010 - 06/23/2011
Internship in Internal Medicine at Mercy Hospital and Medical Center

VIEW ALL expand_more

Clinical Trials

CMMY18034: S1702, A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated Amyloid Light Chain Amyloidosis

Lead Researcher: Frank C Passero

All participants will receive the same study drug. If you decide to participate, you will receive up to 24 cycles (1 cycles = 28 days) of the study drug, isatuximab, as an outpatient (meaning you will not be admitted to the hospital to receive study drug. During the first cycle (or 28 days), you will receive isatuximab on Day 1, 8, 15 and 22 by intravenous (IV) infusion (into your vein). For all other cycles (Cycle 2, up to Cycle 24), you will receive isatuximab on Days 1 and 15.

View Study Details

IMMY17131: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Lead Researcher: Frank C Passero

There are two treatment groups in this study. The study medication will be given in treatment cycles, and each cycle is 28 days long. Group A: Cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD). Group B: Daratumumab plus cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD)

View Study Details


Journal Articles

Evens AM, Konry T, David K, Mokhtar M, Chen Y, Beheshti A, Passero F, Purvey S, Sarkar S, Ravi D. "Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma." Leukemia.. 2019 Nov 26; Epub 2019 Nov 26.

Evens AM, David KA, Beheshti A, McDonald JT, Ravi D, Passero FC. "Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma." British journal of haematology.. 2019 Aug 26; Epub 2019 Aug 26.

Lipe B, Passero FC, Gleber C, Portuguese AJ. "A review of thrombotic microangiopathies in multiple myeloma." Leukemia research.. 2019 Jul 29; 85:106195. Epub 2019 Jul 29.